H Y Dong

Summary

Affiliation: Genzyme Corporation
Country: USA

Publications

  1. ncbi Plasmablastic lymphoma in HIV-positive patients: an aggressive Epstein-Barr virus-associated extramedullary plasmacytic neoplasm
    Henry Y Dong
    Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Am J Surg Pathol 29:1633-41. 2005
  2. ncbi PAX-5 is invariably expressed in B-cell lymphomas without plasma cell differentiation
    H Y Dong
    Genzyme Genetics, New York, NY 10019, USA
    Histopathology 53:278-87. 2008
  3. ncbi CD71 is selectively and ubiquitously expressed at high levels in erythroid precursors of all maturation stages: a comparative immunochemical study with glycophorin A and hemoglobin A
    Henry Y Dong
    Genzyme Genetics, New York, NY, USA
    Am J Surg Pathol 35:723-32. 2011
  4. ncbi KSHV- and EBV-associated germinotropic lymphoproliferative disorder
    Ming Qing Du
    Department of Histopathology, Royal Free and University College Medical School, University College London, Rockefeller Building, University Street, London WC1E 6JJ, UK
    Blood 100:3415-8. 2002
  5. ncbi CD5- mantle cell lymphoma
    Zach Liu
    IMPATH, New York, NY 10019, USA
    Am J Clin Pathol 118:216-24. 2002
  6. ncbi CD30-positive T-cell lymphomas co-expressing CD15: an immunohistochemical analysis
    Wojciech Gorczyca
    IMPATH Inc, New York, NY 10019, USA
    Int J Oncol 22:319-24. 2003
  7. ncbi B-cell lymphomas with coexpression of CD5 and CD10
    Henry Y Dong
    IMPATH Inc, 521W 57th St, 6th Floor, New York, NY 10019, USA
    Am J Clin Pathol 119:218-30. 2003
  8. ncbi Expression of the B cell-associated transcription factors PAX5, OCT-2, and BOB.1 in acute myeloid leukemia: associations with B-cell antigen expression and myelomonocytic maturation
    Sarah E Gibson
    Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH 44195, USA
    Am J Clin Pathol 126:916-24. 2006
  9. ncbi Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H)
    Scott J Rodig
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Clin Cancer Res 12:7174-9. 2006

Collaborators

Detail Information

Publications9

  1. ncbi Plasmablastic lymphoma in HIV-positive patients: an aggressive Epstein-Barr virus-associated extramedullary plasmacytic neoplasm
    Henry Y Dong
    Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Am J Surg Pathol 29:1633-41. 2005
    ..We conclude that most plasmacytic tumors in HIV-positive individuals are extramedullary, clinically aggressive EBV(+) tumors identical to plasmablastic lymphoma that does not have the clinical features of plasma cell myeloma...
  2. ncbi PAX-5 is invariably expressed in B-cell lymphomas without plasma cell differentiation
    H Y Dong
    Genzyme Genetics, New York, NY 10019, USA
    Histopathology 53:278-87. 2008
    ..The B-cell-specific transcription factor PAX-5 is physiologically expressed in normal B cells and silenced in plasma cells. The aim of this study was to determine whether PAX-5 expression is universal among B-cell malignancies...
  3. ncbi CD71 is selectively and ubiquitously expressed at high levels in erythroid precursors of all maturation stages: a comparative immunochemical study with glycophorin A and hemoglobin A
    Henry Y Dong
    Genzyme Genetics, New York, NY, USA
    Am J Surg Pathol 35:723-32. 2011
    ..We conclude that CD71 is selectively expressed at high levels in erythroid precursors, including those at early maturation stages. It can be reliably used as an independent erythroid marker for immunohistochemical analysis of the marrow...
  4. ncbi KSHV- and EBV-associated germinotropic lymphoproliferative disorder
    Ming Qing Du
    Department of Histopathology, Royal Free and University College Medical School, University College London, Rockefeller Building, University Street, London WC1E 6JJ, UK
    Blood 100:3415-8. 2002
    ..We propose calling this distinctive entity "KSHV-associated germinotropic lymphoproliferative disorder."..
  5. ncbi CD5- mantle cell lymphoma
    Zach Liu
    IMPATH, New York, NY 10019, USA
    Am J Clin Pathol 118:216-24. 2002
    ..These data show that MCL may lack CD5 expression. Evaluation of bcl-1 expression by immunohistochemical analysis or molecular genetics may be indicated if MCL is suspected clinically or morphologically despite a lack of CD5 expression...
  6. ncbi CD30-positive T-cell lymphomas co-expressing CD15: an immunohistochemical analysis
    Wojciech Gorczyca
    IMPATH Inc, New York, NY 10019, USA
    Int J Oncol 22:319-24. 2003
    ..It is incumbent upon the pathologist to distinguish between these two clinicopathologic entities, since treatment options and clinical outcomes differ...
  7. ncbi B-cell lymphomas with coexpression of CD5 and CD10
    Henry Y Dong
    IMPATH Inc, 521W 57th St, 6th Floor, New York, NY 10019, USA
    Am J Clin Pathol 119:218-30. 2003
    ..Investigation of bcl-1, bcl-6, and CD43 and morphologic evaluation may resolve the potential confusion in diagnosis and lead to the recognition of the correct lymphoma subtype...
  8. ncbi Expression of the B cell-associated transcription factors PAX5, OCT-2, and BOB.1 in acute myeloid leukemia: associations with B-cell antigen expression and myelomonocytic maturation
    Sarah E Gibson
    Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH 44195, USA
    Am J Clin Pathol 126:916-24. 2006
    ..Although OCT-2 and BOB.1 were not associated with PAX5 expression, we report expression of OCT-2 in AML with myelomonocytic/monocytic maturation and BOB.1 in normal hematopoietic elements...
  9. ncbi Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H)
    Scott J Rodig
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Clin Cancer Res 12:7174-9. 2006
    ..The utility of CAMPATH in the treatment of other hematologic neoplasms has been explored; however, a comprehensive survey of CD52 expression among a broad spectrum of WHO-defined tumor types has not been completed...